VP and Biotech AnalystÂ Pete Stavropoulos, PhD moderated “Who to Target – Leveraging Biomarkers for Patient Selection in Neuro/Psych Clinical Trials.” The panel featuredÂ Amit Etkin, Founder & CEO ofÂ Alto Neuroscience,Â Adrian Adams, Chairman & CEO ofÂ Impel Pharmaceuticals, andÂ Stephen O’Quinn, VP of Medical Affairs atÂ Zynerba Pharmaceuticals.
• The panel focused on applications of precision medicine, from stratifying target patients to optimizing drug delivery
• Zynerba utilizes instruments that capture therapeutic benefit most meaningful to patients and clinicians in autism spectrum disorder, and a rescored version in Fragile X
• Alto has developed an extensive database comprised of EEG data in addition to cognitive and behavior biomarkers to match patients to a specific candidate from its pipeline
• Impel launched Trudhesa, a dihydroergotamine mesylate nasal spray that targets, not the lower nasal space as most migraine sprays do, but the upper nasal space for more predictable and consistent administration